Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ARIAD Announces Appointments of Key Members of Leadership Team

Published: Friday, February 22, 2013
Last Updated: Friday, February 22, 2013
Bookmark and Share
Ready for anticipated regulatory approval and launch of Iclusig® in Europe this year.

ARIAD Pharmaceuticals, Inc. announced the appointment of Jonathan E. Dickinson to the position of General Manager, ARIAD Pharmaceuticals (Europe), Sàrl. Mr. Dickinson is a seasoned commercial executive bringing more than 20 years of pharmaceutical-industry experience to ARIAD, with special emphasis on global and pan-European leadership of several important cancer medicines. Mr. Dickinson is responsible for leading ARIAD’s European commercialization initiatives -- focused first on the anticipated European approval and launch of Iclusig® (ponatinib) in the third quarter of 2013 and subsequently on ARIAD’s other cancer medicines in development.

Mr. Dickinson joined ARIAD from Bristol-Myers Squibb, where he served for the past three years as the European brand lead for ipilimumab, responsible for the product’s European launch and commercialization in 29 countries. Previously, during his 13-year tenure at Hoffmann-La Roche, Mr. Dickinson held several key leadership positions, including lifecycle leader for capecitabine, where he managed global marketing, clinical development, regulatory affairs and manufacturing activities for the brand. At Roche, he had assignments both in the U.S. and Switzerland that included leadership roles of Roche’s three leading oncology medicines -- trastuzumab, rituximab, and capecitabine. Mr. Dickinson began his career at Novartis, where he held commercial roles in its oncology and endocrinology businesses, including medical sales, product manager and business director in the United Kingdom.

Mr. Dickinson received his B.Sc. degree in Genetics and his M.B.A. degree from the University of Nottingham. He is based at ARIAD’s European headquarters in Lausanne, Switzerland and reports to Marty J. Duvall, senior vice president, commercial operations of ARIAD.

“Jonathan is a proven leader with broad commercial and general management experience promoting several of the most highly regarded oncology medicines available today,” stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “His knowledge of the evolving European market and his success in commercializing important cancer medicines throughout Europe and globally will serve us well as we prepare for anticipated approval and commercialization of Iclusig in the EU this year.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ARIAD Presents Data for Investigational Inhibitor
New preclinical data showing AP26113 inhibits clinically relevant mutants of ALK and ROS1.
Thursday, April 11, 2013
New Study by ARIAD Scientists Offers Insights into Design of Small-Molecule Drugs to Treat Drug-Resistant Leukemia
ARIAD publishes the high-resolution structure of the protein responsible for a major clinically relevant genetic variant of drug-resistant chronic myeloid leukemia.
Wednesday, October 10, 2007
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!